Relmada Therapeutics, Inc.
RLMD Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$3.23
KIRA · Stoqly’s AI analyst, in plain words
- Relmada Therapeutics, Inc. lost $57.4M in fiscal 2025.
Market cap
$363M
P/E
—
Revenue
—
Net income
−$57.4M
Free cash flow
—
Operating margin
—
Relmada Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$57.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Relmada Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 19, 2026
- Legal name
- RELMADA THERAPEUTICS, INC.
- CIK
- 0001553643
Relmada Therapeutics, Inc. · RLMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.2M | $2.7M | $5.2M | — | — |
| Revenue growth | −14.3% | 121.8% | 93.7% | — | — |
| Net interest income | $1.2M | $2.7M | $5.2M | — | — |
| Operating margin | −10,483.2% | −6,063.4% | −2,013.0% | — | — |
| Net income | −$126M | −$157M | −$98.8M | −$80.0M | −$57.4M |
| Net margin | −10,487.2% | −5,905.2% | −1,917.7% | — | — |
| Diluted EPS | −$7.16 | −$5.30 | −$3.28 | −$2.65 | −$1.45 |
| Cash | |||||
| Cash from operations | −$91.9M | −$104M | −$51.7M | −$51.8M | −$45.8M |
| Share count change | 12.6% | 68.8% | 1.6% | 0.2% | 30.9% |
| Debt and strength | |||||
| Cash and short-term investments | $212M | $148M | $96.3M | $44.9M | $93.0M |
| Shareholders' equity | $208M | $140M | $85.4M | $35.5M | $86.5M |
| Current ratio | 14.8x | 12.3x | 8.0x | 4.4x | 14.6x |
| Returns and quality | |||||
| Return on equity | −80.1% | −90.1% | −87.5% | −132.3% | −94.0% |
| Return on tangible equity | −60.4% | −111.8% | −115.7% | −225.2% | −66.3% |
| Piotroski F-score | 2 | 2 | 3 | — | — |
| Altman Z'' | 12.4 | 0.9 | −12.8 | −49.2 | −10.2 |
Insiders bought, 12 months
$4.0M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Relmada Therapeutics, Inc. · RLMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.23 a share, the company is worth $363M.
Source: SEC EDGAR XBRL filings (CIK 0001553643). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.